No material news was released; the conferences may provide a venue for pipeline updates. Monitor for any clinical data or partnership announcements that could emerge from these events.
Drugs in focus
MT-001
● Neutral Named in this press release- Impact
- Phase
- Preclinical (IND-enabling)
- Time to market
- Unknown — still preclinical. If successful through Phases 1-3, a potential approval would be 5+ years away.
- Next catalyst
- None dated
What to watchMT-001 is too early for a binary trade, no human data exists yet and Phase 2a data is two+ years out. The real near-term story for INM is the reverse-merger close (expected by Dec 31, 2026) and whether the $290M PIPE fully funds through 2028 as promised. Post-merger the ticker changes, so current INM holders are effectively buying Mentari's preclinical pipeline at the merged entity's valuation. Watch for the IND/CTA filing mid-2026 as a first proof of life.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 9 $16.00entry
- T+1 · 7d ago −23.75%α −23.38% · $12.20
- T+5 · 20h ago +24.19%α +25.88% · $19.87
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mentari Therapeutics announced management participation in three upcoming investor conferences in November 2026. This is a routine investor relations activity with no material financial or clinical data disclosed.
Key Facts
- Management to present at Guggenheim 3rd Annual Healthcare Innovation Conference on Nov 9, 2026 at 4:00 p.m. ET
- Management to present at Stifel 2026 Healthcare Conference on Nov 12, 2026 at 10:00 a.m. ET
- Management to present at 2026 Jefferies Global Healthcare Conference in London on Nov 17, 2026 at 11:00 a.m. GMT
- Webcasts will be archived on Mentari's website for 90 days following each conference
- Lead programs are MT-001 (anti-PACAP mAb) and MT-002 (anti-PACAP/anti-CGRP bispecific) for migraine prevention
Financial Impact
No financial data disclosed in the release
Risk Factors
- No clinical data or financial guidance was provided in this release
- Investor conferences may not result in material disclosures
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398334 |
Track record
10 reports on MTRI
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $17.90 Now $19.87 −11.01% settles Dec 15
- Nov 16, 2026today 8-K Neutral 6/10 Entry $18.60 Now $19.87 +6.83% settles Dec 15
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $19.02 Now $19.87 +4.47% settles Dec 15
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $15.75 Now $19.87 +26.16% settles Dec 15
- Nov 12, 20264d ago SC 13D Neutral 5/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 10, 20266d ago 8-K Mixed 7/10 Entry $15.61 Now $19.87 +27.30% settles Dec 10
- Nov 9, 20267d ago Press Release Neutral 2/10 Viewing Entry $16.00 Now $19.87 +24.19% settles Dec 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers